Design, synthesis, and biological evaluation of novel piperidine-4- carboxamide derivatives as potent CCR5 inhibitors

European Journal of Medicinal Chemistry

Volumn 71, Issue , 2014, Pages 259-266

  Hu, Suwen ^a   Gu, Quan ^a   Wang, Zhilong ^b   Weng, Zhiyong ^a,c   Cai, Yunrui ^a   Dong, Xiaowu ^a   Hu, Yongzhou ^a   Liu, Tao ^a   Xie, Xin ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c Hangzhou No 2 High School   (China)

Author keywords

Anti HIV 1 agent; CCR5 inhibitor; Piperidine 4 carboxamide derivatives

Indexed keywords

AMIDE; CALCIUM; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; MARAVIROC; PIPERIDINE DERIVATIVE; TERT BUTYL 4 (4 CHLOROBENZYLCARBAMOYL)PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 (4 CHLOROPHENETHYLCARBAMOYL)PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 (4 CYANOBENZYLCARBAMOYL)PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 (4 FLUOROBENZYLCARBAMOYL)PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 (4 FLUOROPHENETHYLCARBAMOYL)PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 (BENZYLCARBAMOYL)PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 (PHENETHYLCARBAMOYL)PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 (PHENYLCARBAMOYL)PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [BENZYL(ETHYL)CARBAMOYL]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [BENZYL(METHYL)CARBAMOYL]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [ETHYL(4 FL UOROPHENETHYL)CARBAMOYL]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [ETHYL(4 FLUOROBENZYL)CARBAMOYL]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [ETHYL(4 METHYLBENZYL)CARBAMOYL]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [ETHYL(PHENETHYL)CARBAMOYL]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [ETHYL(PHENYL)CARBAMOYL]PIPERIDINE 1 CARBOXYLATE; UNCLASSIFIED DRUG; 1 ACETYL N (3 CHLOROPHENYL) N [3 [4 (4 CYANOBENZYLCARBAMOYL)PIPERIDIN 1 YL]PROPYL]PIPERIDINE 4 CARBOXAMIDE; 1 ACETYL N (3 CHLOROPHENYL) N [3 [4 (4 FLUOROBENZYLCARBAMOYL)PIPERIDIN 1 YL]PROPYL]PIPERIDINE 4 CARBOXAMIDE; 1 ACETYL N (3 CHLOROPHENYL) N [3 [4 (4 FLUOROPHENETHYLCARBAMOYL)PIPERIDIN 1 YL]PROPYL]PIPERIDINE 4 CARBOXAMIDE; 1 ACETYL N (3 CHLOROPHENYL) N [3 [4 (PHENETHYLCARBAMOYL) PIPERIDIN 1 YL]PROPYL]PIPERIDINE 4 CARBOXAMIDE; 1 ACETYL N (3 CHLOROPHENYL) N [3 [4 (PHENYLCARBAMOYL) PIPERIDIN 1 YL]PROPYL]PIPERIDINE 4 CARBOXAMIDE; 1 ACETYL N (3 CHLOROPHENYL) N [3 [4 [(4CYANOBENZYL)(ETHYL)CARBAMOYL]PIPERIDIN 1 YL]PROPYL]PIPERIDINE 4 CARBOXAMIDE; 1 ACETYL N (3 CHLOROPHENYL) N [3 [4 [ETHYL(4 FLUOROBENZYL) CARBAMOYL]PIPERIDIN 1 YL]PROPYL]PIPERIDINE 4 CARBOXAMIDE; 1 ACETYL N (3 CHLOROPHENYL) N [3 [4 [ETHYL(4 FLUOROPHENETHYL)CARBAMOYL]PIPERIDIN 1 YL]PROPYL]PIPERIDINE 4 CARBOXAMIDE; 1 ACETYL N (3 CHLOROPHENYL) N [3 [4 [ETHYL(4 METHYLBENZYL)CARBAMOYL]PIPERIDIN 1 YL]PROPYL]PIPERIDINE 4 CARBOXAMIDE; 1 ACETYL N (3 CHLOROPHENYL) N [3 [4 [ETHYL(PHENETHYL) CARBAMOYL]PIPERIDIN 1 YL]PROPYL]PIPERIDINE 4 CARBOXAMIDE; 1 ACETYL N (3 CHLOROPHENYL) N [3 [4 [ETHYL(PHENYL) CARBAMOYL]PIPERIDIN 1 YL]PROPYL]PIPERIDINE 4 CARBOXAMIDE; 1 ACETYL N [3 [4 (4 CHLOROBENZYLCARBAMOYL)PIPERIDIN 1 YL] PROPYL] N (3 CHLOROPHENYL)PIPERIDINE 4 CARBOXAMIDE; 1 ACETYL N [3 [4 (4 CHLOROPHENETHYLCARBAMOYL)PIPERIDIN 1 YL]PROPYL] N (3 CHLOROPHENYL)PIPERIDINE 4 CARBOXAMIDE; 1 ACETYL N [3 [4 (BENZYLCARBAMOYL)PIPERIDIN 1 YL]PROPYL] N (3 CHLOROPHENYL)PIPERIDINE 4 CARBOXAMIDE; 1 ACETYL N [3 [4 [(4 CHLOROBENZYL)(ETHYL)CARBAMOYL] PIPERIDIN 1 YL]PROPYL] N (3 CHLOROPHENYL)PIPERIDINE 4 CARBOXAMIDE; 1 ACETYL N [3 [4 [(4 CHLOROPHENETHYL)(ETHYL)CARBAMOYL] PIPERIDIN 1 YL]PROPYL] N (3 CHLOROPHENYL)PIPERIDINE 4 CARBOXAMIDE; 1 ACETYL N [3 [4 [BENZYL(ETHYL)CARBAMOYL]PIPERIDIN 1 YL] PROPYL] N (3 CHLOROPHENYL)PIPERIDINE 4 CARBOXAMIDE; 1 ACETYL N [3 [4 [BENZYL(METHYL)CARBAMOYL]PIPERIDIN 1 YL] PROPYL] N (3 CHLOROPHENYL)PIPERIDINE 4 CARBOXAMIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PIPERIDINE 4 CARBOXAMIDE DERIVATIVE; TERT BUTYL 4 [(4 CHLOROBENZYL)(ETHYL)CARBAMOYL]PIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [(4 CYANOBENZYL)(ETHYL)CARBAMOYL]PIPERIDINE 1 CARBOXYLATE; UNINDEXED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CALCIUM MOBILIZATION; CONTROLLED STUDY; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; NONHUMAN; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; CALCIUM MOBILIZATION ASSAY; CYTOTOXICITY ASSAY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; HEK293 CELL LINE; IC50; PATCH CLAMP TECHNIQUE; PHARMACOPHORE; RAT; VIRUS INFECTIVITY; VOLUME OF DISTRIBUTION AT STEADY-STATE;

ANTI-HIV-1 AGENT; CCR5 INHIBITOR; PIPERIDINE-4-CARBOXAMIDE DERIVATIVES;

ANTI-HIV AGENTS; DRUG DESIGN; HIV INFECTIONS; HIV-1; HUMANS; PIPERIDINES; RECEPTORS, CCR5; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84888988839     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.11.013     Document Type: Article

References (13)

1. E.A. Berger, P.M. Murphy, and J.M. Farber Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease Annu. Rev. Immunol. 17 1999 657 700 (Pubitemid 29241137)
2. L. Wu, N.P. Gerard, R. Wyatt, H. Choe, C. Parolin, N. Ruffing, A. Borsetti, A.A. Cardoso, E. Desjardin, W. Newman, C. Gerard, and J. Sodroski CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR5 Nature 384 1996 179 183 (Pubitemid 26386475)
3. P.D. Kwong, R. Wyatt, J. Robinson, R.W. Sweet, J. Sodroski, and W.A. Hendricks Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody Nature 393 1998 648 659 (Pubitemid 28289647)
4. R. Liu, W.A. Paxton, S. Choe, D. Ceradini, S.R. Martin, R. Horuk, M.E. MacDonald, H. Stuhlmann, R.A. Koup, and N.R. Landau Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection Cell 86 1996 367 377 (Pubitemid 26272077)
5. M. Nishikawa, K. Takashima, T. Nishi, R.A. Furuta, N. Kanzaki, Y. Yamamoto, and J. Fujisawa Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5 Antimicrob. Agents Chemother. 49 2005 4708 4715 (Pubitemid 41552603)
6. O.M. Klibanov, S.H. Williams, and C.A. Iler Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection Curr. Opin. Investig. Drugs 11 2010 940 950
7. T. Liu, Z. Weng, X. Dong, and Y. Hu Recent advances in the development of small-molecule CCR5 inhibitors for HIV Mini-Rev. Med. Chem. 10 2010 1277 1292
8. M.X. Dong, L. Lu, X. Wang, H. Lu, S. Jiang, and Q.Y. Dai Design, synthesis, and biological activity of novel 1,4-disubstituted piperidine/piperazine derivatives as CCR5 antagonist-based HIV-1 entry inhibitors Bioorg. Med. Chem. Lett. 22 2012 3284 3286
9. T. Liu, Z. Weng, X. Dong, L. Chen, L. Ma, S. Cen, N. Zhou, and Y. Hu Design, synthesis and biological evaluation of novel piperazine derivatives as potential CCR5 antagonists PLoS ONE 8 2013 e53636
10. Y.Q. Long, D.Z. Feng, L. Chen, R.H. Chen, 1-(3-Amino-propyl)-piperidin-4- yl-amides, pharmaceutical compositions, processes for their preparation and uses, PCT Int. Appl., 30 April, 2009, WO 2009052708 A1, 27.
11. J. Klaveness, B. Brudeli, F.O. Levy, 5-HTX modulators, PCT Int. Appl., 18 Jan, 2007, WO 2007007072 A1, 17.
12. R.L. Duncan Jr., G.C. Helsley, W.J. Welstead Jr., J.P. DaVanzo, W.H. Funderburk, and C.D. Lunsford Aroylpiperidines and pyrrolidines. A new class of potent central nervous system depressants J. Med. Chem. 13 1970 1 6
13. S. Imamura, T. Ichikawa, Y. Nishikawa, N. Kanzaki, K. Takashima, S. Niwa, Y. Iizawa, M. Baba, and Y. Sugihara Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent anti-HIV-1 activity J. Med. Chem. 49 2006 2784 2793